Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC28910.15690/vramn.v67i7.341SHORT MESSAGESКРАТКИЕ СООБЩЕНИЯENDOTHELIAL PROTECTION DRUGS ― A NEW CLASS OF PHARMACOLOGICAL AGENTSЭНДОТЕЛИОПРОТЕКТОРЫ ― НОВЫЙ КЛАСС ФАРМАКОЛОГИЧЕСКИХ ПРЕПАРАТОВTyurenkovI. N.ТюренковИ. Н.
Russian Federation

член-корреспондент РАМН, профессор, заведующий кафедрой фармакологии и био- фармации ФУВ ГБОУ ВПО ВолгГМУ Минздравсоцразвития России, заведующий лабораторией фармакологии сердечно-сосудистых средств НИИ фармакологии ГБОУ ВПО ВолгГМУ Минздравсоцразвития России Адрес: 400001, Волгоград, ул. Пугачевская, д. 3 Тел./факс: (8442) 97-81-80

fibfuv@mail.ruVoronkovA. V.ВоронковА. В.
Russian Federation

доктор медицинских наук, старший научный сотрудник лаборатории фармакологии сердечно-сосудистых средств НИИ фармакологии ГБОУ ВПО ВолгГМУ Минздравсоцразвития России Адрес: 400001, Волгоград, ул. Пугачевская, д. 3 Тел./факс: (8442) 97-81-80

prohor77@mail.ruSlietsansA. A.СлиецансА. А.
Russian Federation

кандидат фармацевтических наук, научный сотрудник лаборатории фармакологии сердечно-сосудистых средств НИИ фармакологии ГБОУ ВПО ВолгГМУ Минздравсоцразвития России Адрес: 400001, Волгоград, ул. Пугачевская, д. 3 Тел./факс: (8442) 97-81-80

fibfuv@mail.ruVolotovaE. V.ВолотоваЕ. В.
Russian Federation

кандидат медицинских наук, ассистент кафедры фармакологии и биофармации ФУВ ГБОУ ВПО ВолгГМУ Минздравсоцразвития России Адрес: 400001, Волгоград, ул. Пугачевская, д. 3 Тел./факс: (8442) 97-81-80 E-mail: a-zlato@mail.ru

fibfuv@mail.ruVolgograd State Medical University, Department of Pharmacology and Biopharmaceutics Cardiovascular Agents Laboratory of the Research Institute of PharmacologyГБОУ ВПО Волгоградский государственный медицинский университет Минздравсоцразвития России НИИ фармакологии ВолгГМУ Минздравсоцразвития РоссииCardiovascular Agents Laboratory of the Research Institute of PharmacologyНИИ фармакологии ВолгГМУ Минздравсоцразвития РоссииVolgograd State Medical University, Department of Pharmacology and BiopharmaceuticsГБОУ ВПО Волгоградский государственный медицинский университет Минздравсоцразвития России10072012677Вестник Российской академии медицинских наук505707082015Copyright ©; 2012, "Paediatrician" Publishers LLCCopyright ©; 2012, Издательство "Педиатръ"2012"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/about/submissionshttps://vestnikramn.spr-journal.ru/jour/article/view/289

This review considers issues dealing with the role of nitric oxide and endothelial function/dysfunction in providing a number of physiological and pathophysiological processes and various body systems functioning. It also covers in details the possible ways of pharmacological management of endothelial dysfunction (ED) using drugs of different pharmacological groups (classes). Diverse pharmacological effects which have various degree of intensity and presented at various stages of ED pathogenesis are discussed. The value and urgency of search and development of agents with endothelial protection potential are studied in available experimental and clinical works on the considerable role of endothelial system in cardiovascular diseases and lack of specific means for prevention and treatment of endothelial dysfunction. Integrated morphological-functional approach to assessment of ED and endothelial protection of substances was developed and implemented in experimental practice in Cardiovascular Agents Laboratory of the Volgograd State Medical University Research Institute of Pharmacology. Various ED models were tested and most valid ones were selected. Еndothelial protection of new compounds such as Salifen and Flavicin are considered and compared with cardiovascular drugs, antioxidants with metabolic effects, GABA derivatives. These drugs are assumed to belong to a new class of drugs – endothelial protection drugs.

В обзоре рассмотрена эндотелиальная функция/дисфункция в обеспечении ряда физиологических и патофизиологических процессов, а также функционирования различных систем организма. Проведен анализ возможных путей фармакологической коррекции эндотелиальной дисфункции (ЭД). Исходя из существующих экспериментальных и клинических данных о важной роли эндотелиальной системы в развитии сердечно-сосудистых заболеваний, с одной стороны, а с другой ― отсутствия специфических средств профилактики и лечения ЭД, рассматривается целесообразность и актуальность поиска и разработки лекарственных средств с эндотелиопротекторным действием (ЭПД). При решении подобных задач, связанных с поиском и разработкой нового класса лекарственных средств, в лаборатории фармакологии сердечно-сосудистых средств НИИ фармакологии ВолгГМУ был разработан и внедрен в экспериментальную практику комплексный морфофункциональный подход к оценке ЭД и ЭПД веществ, а также прошли тестирование многие модели ЭД. В результате целенаправленного поиска среди производных ГАМК и флавоноидов выделены новые перспективные соединения ― флавицин (флавоноид) и салифен (производное ГАМК), обладающие более выраженными ЭПД, чем сердечно-сосудистые средства, антиоксиданты с метаболотропными эффектами, остальные изученные производные ГАМК.

nitric oxideendothelial functionendothelial dysfunction (ED)endothelial protectionSalifenFlavicinоксид азотаэндотелиальная функция/дисфункцияэндотелиопротекторысалифенфлавицин1. Petrishchev N.N. Disfunqtciia e`ndoteliia. Prichiny`, mehanizmy`, farmaqologichesqaia qorreqtciia. SPb. 2003. 184 s.2. Markov KH.M. Oqsidativny`i` stress i disfunqtciia e`ndoteliia. Patologichesqaia fiziologiia i e`qsperimental`naia terapiia. 2005; 4: 5–9.3. Butrova S.A. Metabolichesqii` sindrom: patogenez, cliniqa, diagnostiqa, podhody` q lecheniiu. Russqii` meditcinsqii` zhurnal. 2001; 2: 56–60.4. Pitocco D. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010; 7 (1): 15–25.5. Dzhanashiia P.KH. Remodelirovanie serdtca i ego rol` v formirovanii aritmii` u bol`ny`kh saharny`m diabetom tipa 2 i arterial`noi` gipertoniei`. Rossii`sqii` qardiologichesqii` zhurnal. 2008; 6: 10–14.6. Tiurenqov I.N., Voronqov A.V., Robertus A.I Razvitie e`ndotelial`noi` disfunqtcii pri nedostatochnosti polovy`kh gormonov. Patologichesqaia fiziologiia i e`qspepimental`naia tepapiia. 2009; 4: 33–36.7. Kalmy`qov Iu.M. Gomotcistein – prediqtor patologichesqikh izmenenii` v organizme cheloveqa. Russqii` meditcinsqii` zhurnal. 2009; 17 (4): 224–228.8. Campisi R., Czernin J., Scheder H. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation. 1998; 98: 119–25.9. Zeiher A. M., Schachinger V., Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 1995; 92: 1094–1100.10. Petrosian K.R., Avtandilov A.G. Struqturno-funqtcional`ny`e izmeneniia arterii` u quriashchikh muzhchin v vozrastnom aspeqte. Rossii`sqii` qardiologichesqii` zhurnal. 2008; 3: 35–40.11. Shumakher G.I. Rol` disfunqtcii e`ndoteliia v zapusqe immunopatologichesqikh reaqtcii` pri khronichesqoi` ishemii golovnogo mozga. Biulleten` Sibirsqoi` meditciny`. 2008; 5: 214–219.12. Endres M., Heuschmann P.U., Laufs U., Hakim A.M. Primary prevention of stroke: blood pressure, lipids, and heart failure. Eur Heart J. 2011; 32: 545–552.13.Maltais S. The bone marrow-cardiac axis: role of endothelial progenitor cells in heart failure. Eur J Cardiothorac Surg. 2011; 39: 368–374.14. Chugun ova L.A., Shestaqova M.V., Shamhalova M.Sh. Primenenie gliqozaminogliqanov v lechenii diabetichesqoi` nefropatii. Saharny`i` diabet. 2009; 3 (4): 34–36.15. Tessari P., Cecchet D., Cosma A. et al. Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy. Diabetes. 2010; 59: 2152–2159.16. Vorob`eva E.N., Shumakher G.I., Horeva M.A., Osipova I.V. Disfunqtciia e`ndoteliia – cliuchevoe zveno v patogeneze ateroscleroza. Rossii`sqii` qardiologichesqii` zhurnal. 2010; 2: 84–91.17. Markov KH.M. L-arginin — oqsid azota v terapii boleznei` serdtca i sosudov. Kardiologiia. 2005; 6: 87–95.18. Markov KH.M. Oqsid azota i ateroscleroz. Oqsid azota, disfunqtciia sosudistogo e`ndoteliia i patogenez ateroscleroza. Kardiologiia. 2009; 11: 64–74.19. Karpov Iu.A. Disfunqtciia arterial`nogo e`ndoteliia i ee znachenie dlia ocenqi prognoza u bol`ny`kh serdechno-sosudisty`mi zabolevaniiami. Kardiovasquliarnaia terapiia i profilaqtiqa. 2010; 2: 69–73.20. Bondarenqo V.M. Immunolog ichesqie i molequliarno-genetichesqie osnovy` patogeneza khronichesqikh vospalitel`ny`kh zabolevanii` qishechniqa. Immunologiia. 2010; 4: 215–219.21. Zvenigorodsqaia L.A., Nilo va T.V. Oqsid azota qaq marqer vospaleniia pri steatogepatite u bol`ny`kh s metabolichesqim sindromom. Russqii` meditcinsqii` zhurnal. 2008; 10 (2): 47–50.22. Bashqirova Iu.V. E`ndotelial`naia disfunqtciia i miqrotcirquliatorny`e narusheniia u bol`ny`kh saharny`m diabetom 2 tipa. Biulleten` Sibirsqoi` meditciny`. 2008; 6: 182–186.23. Smirnov I.E., Volqov I.K., K ucherenqo A.G. i dr. Interlei`qiny` i oqsid azota pri poroqakh razvitiia legqikh i bronhov u detei`. Rossii`sqii` pediatrichesqii` zhurnal. 2010; 1: 12–17.24. Tamargo J., Caballero R., Gоmez R., Delpоn E. Cardiac electrophysiological effects of nitric oxide. Cardiovasc Res. 2010; 87: 593–600.25. Versari D., Daghini E., Virdis A . et al. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009; 32: 314–21.26. Neroev V.V., Davy`dova G.A., Perova T.S. Primenenie donorov oqsida azota i ingibitorov NO-sintaz pri uveitakh, travmakh i drugoi` oftal`mopatologii. Clinichesqaia oftal`mologiia. 2005; 4 (6): 172–175.27. Stepanov Iu.M., Kononov I.N., ZHurbina A.I. Arginin v meditcinsqoi` praqtiqe (obzor literatury`). ZHurnal AMN Uqrainy`. 2004; 10 (1): 340–352.28. Severina I.S., Piataqova N.V., Busy`gina O.G. Rastvorimaia guanilattciclaza v mehanizme dei`stviia fiziologichesqikh e`ffeqtov oqsida azota. Voprosy` meditcinsqoi` himii. 1999; 5: 435–436.29. Novy`i` podhod q lecheniiu bol`ny`kh e`reqtil`noi` disfunqtciei`: postoianny`i` priem ingibitorov fosfodie`sterazy` 5 tipa (Obzor literatury`) Russqii` meditcinsqii` zhurnal. 2008; 9: 620–624.30. Duvall W.L. Endothelial dysfunction and antioxidants. Mt Sinai J Med. 2005; 72 (2): 71–80.31. Frei B. On the role of vitamin C and o ther antioxidants in atherogenesis and vascular dysfunction. Proc Soc Exp Biol Med. 1999; 222 (3): 196–204.32. Azen S.P., Qian D., Mack W.J. et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation. 1996; 94: 2369–2372.33. Silvestro A., Scopacasa F., Oliva G. et al. Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication. Atherosclerosis. 2002; 165 (2): 277–284.34. KHlebodarov F.E. Disfunqtciia sosudistogo e`ndoteliia i ee qorreqtciia tcitoproteqtorami u bol`ny`kh stabil`noi` stenoqardiei` napriazheniia i arterial`noi` gipertoniei`. Rossii`sqii` qardiologichesqii` zhurnal. 2009; 6: 34–39.35. Eliott T.G., Barth J.D., Mancini G.B. Effects of vitamin E on endothelial function in men after myocardial infarction. Am J Cardiol. 1995; 76 (16): 1188–1190.36. Aiello L.P. Effect of ruboxistaurin in patients with diabetic macular edema. Arch Ophthalmol. 2007; 125: 318–324.37. Medvedev I.N., Gamolina O.V. Vliianie lizin oprila na trombotcitarnuiu aqtivnost` u bol`ny`kh arterial`noi` gipertoniei` s narusheniem tolerantnosti q gliuqoze. Rossii`sqii` qardiologichesqii` zhurnal. 2008; 3: 45–49.38. Cohen P.B., Cope R.L., Michel O. Measurement of cardiac output in anaesthetized animals by the rivodilution methоd. Am J Physiol. 1980; 239 (17): 416–42139. Patel A., MacMahon S., Chalmers J. et al. Effec ts of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829–840.40. Zadionchenqo V.S., Adasheva T.V. Disfunqtciia e`ndoteliia i arterial`naia gipertoniia: terapevtichesqie vozmozhnosti. Rossii`sqii` meditcinsqii` zhurnal. 2001; 1 (145): 11–1541. Medvedev I.N., Kumova T.A. Oslablenie agregatcion noi` sposobnosti trombotcitov u bol`ny`kh arterial`noi` gipertoniei` pri metabolichesqom sindrome na fone lozartana. Rossii`sqii` qardiologichesqii` zhurnal. 2008; 5: 53–56.42. Taddei S. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002; 62: 265–284.43. Krasnova N.M. Vliianie qombinatcii` verapamila s e `nalaprilom i indapamidom na plazmenny`i`, sosudisto-trombotcitarny`i` gemostaz i biohimichesqie marqery` disfunqtcii e`ndoteliia u bol`ny`kh arterial`noi` gipertenziei` s metabolichesqim sindromom. Rossii`sqii` qardiologichesqii` zhurnal. 2008; 3: 49–55.44. Olei`niqov V.E`. Vliianie qarvedilola na insulinorezistentnost` qaq faqtor, opredeliaiushchii` clinichesquiu e`ffeqtivnost` pri metabolichesqom sindrome. Rossii`sqii` qardiologichesqii` zhurnal. 2009; 9: 59–65.45. Aleeva G.N., ZHuravleva M.V., Sapel`niqova E`.R. Gipolipidemichesqaia terapiia u bol`ny`kh saharny`m diabetom 2 tipa. Rossii`sqii` meditcinsqii` zhurnal. 2005; 13 (6): 377.46. Ametov A.S., Soqareva E.V. Statiny` v profilaqtiqe i upravlenii saharny`m diabetom tipa 2. Rossii`sqii` meditcinsqii` zhurnal. 2007; 15 (11): 922–925.47. Tawfik H.E. Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharm Exp Ther. 2006; 319 (1): 386–395.48. Svetuhin A.M., Zemlianoi` A.B. Rezul`taty` primeneniia sulodeqsida u bol`ny`kh s diabetichesqoi` stopoi` bez qritichesqoi` ishemii. Terapevtichesqii` arhiv. 2001; 4: 31–33.49. Broekhuizen L.N. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53 (12): 2646–55.50. Tiurenqov I.N., Voronqov A.V. Metodichesqii` podhod q oc enqe e`ndotelial`noi` disfunqtcii v e`qsperimente. E`qsperimental`naia i clinichesqaia farmaqologiia. 2008; 71 (1): 49–51.51. Tiurenqov I.N. Novaia meditcinsqaia tekhnologiia: ispol`zovanie vy`soqochastotnoi` ul`trazvuqovoi` dopplerografii dlia izucheniia vliianiia farmaqologichesqikh veshchestv na regionarnoe qrovoobrashchenie i e`ndotelial`nuiu funqtciiu: Metodichesqoe posobie. Volgograd: Izd-vo VolGMU. 2010. 28 s.52. Voronqov A.V., Robertus A.I., Tiurenqov I.N. Izuchenie «L-argininovogo paradoqsa» dlia ocenqi e`ndotelial`noi` funqtcii v norme i patologii. Regionarnoe qrovoobrashchenie i miqrotcirquliatciia. 2008; 3 (27): 54–57.53. Kurza K.D. Rat model of arterial thrombosis induced by ferric chloride. Thrombosis Research. 1990; 60 (4): 269–280.54. Petrishchev N.N., Berqovich O.A., Vlasov T.D. Diagnostichesqaia cennost` opredeleniia desqvamirovanny`kh e`ndotelial`ny`kh cletoq v qrovi. Clinichesqaia i laboratornaia diagnostiqa. 2001; 1: 50–52.55. Hladovec J. Desquamation of endothelial cell. Physiol. Bohemoslov. 1978; 27: 140–144.56. Petrov V.I. Vliianie gamma-aminomaslianoi` qisloty` i glitcina n a somato-simpatichesqie refleqsy`. V qn.: Farmaqologiia protcessov reguliatcii qrovoobrashcheniia. Volgograd. 1977. S. 105–109.57. Petrov V.I., Lebedev V.P. GAMKergichesqii` nishodiashchii` put` tormozheniia simpatichesqikh preganglionarny`kh nei`ronov boqovy`kh rogov spinnogo mozga. V qn.: Farmaqologiia protcessov reguliatcii qrovoobrashcheniia. Volgograd. 1979. S. 50–5358. Tiurenqov I.N., Voronqov A.V., Slietcans A.A. i dr. Zavisimost` mezhdu antioqsidantny`m dei`stviem flavonoidov i ikh vliianiem na vazodilatiruiushchuiu funqtciiu e`ndoteliia v usloviiakh e`ndotelial`noi` disfunqtcii. E`qsperimental`naia i clinichesqaia farmaqologiia. 2010; 73 (10): 14–17.59. Yamamoto M. Short-term effects of glucosyl hesperidin and blood pres sure and vascular endothelial function in spontaneously hypertensive rats. J Nutr Sci Vitaminol. 2008; 54 (1): 95–98.60. Th.Wallerath A blend of phenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide. 2005; 12: 97–104.61. Lorenz M. A constituent of green tea, epigallocatechin-3-gallate, acti vates endothelial nitric oxide synthase by a phosphatidylinositol- 3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. 2004; 279 (7): 6190–6195.62. Dias A.S. Quercetin decreases oxidative stress, NF-kappaB activation, a nd iNOS overexpression in liver of streptozotocin-induced diabetic rats. J Nutr. 2005; 135 (10): 2299–2304.63. Chi Y.S., Cheon B.S., Kim H.P. Effect of wogonin, a plant flavone from Scutellaria radix, on the suppression of cyclooxygenase-2 and the induction of inducible nitric oxide synthase in lipopolysaccharide-treated RAW 264.7 cells. Biochem Pharmacol. 2001; 61 (10): 1195–1203.64. Cotelle N. Role of flavonoids in oxidative stress. Curr Top Med Chem. 200 1; 1 (6): 569–590.65. Wang L. Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem. 2006; 54 (26): 9798–9804.66. Perez-Vizcaino F. Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic Res. 2006; 40 (10): 1054–1065.67. Freedman J.E. Select flavonoids and whole juice from purple grapes inhibit p latelet function and enhance nitric oxide release. Circulation. 2002; 103 (23): 2792–2798.68. Perez-Viacaino F. Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic Res. 2006; 40 (10): 1054–1065.69. Virdis A. Endothelial dysfunction, vascular damage and clinical events: role o f antioxidant therapy. High Blood Press. Cardiovasc Prev. 2004; 11: 15– 27.70. Nakayama T., Hattori M., Uchida K. et al. The regulatory domain of the inositol 1, 4, 5-trisphosphate receptor is necessary to keep the channel domain closed: possible physiological significance of specific cleavage by caspase 3. Biochem J. 2004; 377 (2): 299–307.